

## Index

### a

acquired immunodeficiency syndrome (AIDS) 332ff., 347f  
 acute-phase response 29, 30  
 adaptive immunity 92, 164  
 aerosol infection 391  
 allele 306  
 alveolar macrophages (AMs) 3  
 Alzheimer's disease 13  
 animal model 278ff., 292, 294, 306, 389f.  
 – compared to humans 309ff.  
 – genetic variation 306  
 – murine model 390  
 – non-human primate model 408  
 – rabbit model 401  
 antibody  
 – detection methods 230f.  
 – diagnosis 228  
 – host genetics 237  
 – natural antibodies 230  
 – pathogenesis 228  
 – strain-specific differences 236  
 antibody response 227  
 – course 228ff.  
 antigen  
 – discovery strategies 128  
 – phase-specific antigen 130  
 – post-genomic antigen 129  
 – production in dormant *M. tuberculosis* 234  
 – production in rapidly deciding *M. tuberculosis* 235  
 – specificity 234  
 antigen presentation 49  
 antigen-presenting cells (APCs) 23, 45ff., 160, 196  
 anti-microbial peptides 73ff.  
 apoptosis 12, 65, 75, 132, 193, 195, 198  
 – mediator 75  
 autophagy 1ff., 12

– defense against *M. tuberculosis* 71  
 – induction 12

### b

B cell responses 230  
 B cells 73, 186, 227, 238, 248, 252ff., 391  
 bacteria-host interactions 32ff.  
 bacterial signaling 30ff.  
 biomarkers 140  
 booster vaccine 379  
 brain 403

### c

calcification 268  
 calmodulin (CaM) 11  
 carbohydrate recognition domain (CRD) 2  
 caseation 394  
 caseous granuloma 411, 412, 416  
 caseous necrosis 393, 406  
 cathelicidin 74  
 cathepsin 375  
 CD1-restricted T cells 157ff.,  
 – animal models 171  
 – antigen-independent activation 163  
 – distribution in infections 161  
 – effector functions 161  
 – frequency in infections 389  
 – group I responses 164  
 – group II responses 162  
 – introduction 157f.  
 – recognition of infected cells 163  
 – relevant effector functions 164  
 CD4 T cells 161, 288, 348, 351, 394  
 – redundant functions in TB protection 132  
 CD8 T cells 63, 158, 391, 393  
 – antigenic repertoire 135ff.  
 – antigen processing and presentation 134ff.  
 – epitopes 135  
 – immunodominant CD8 antigens 137

- in human tuberculosis 206
  - in TB protection 132ff.
  - redundant functions in TB protection 132
  - cellular immune response 63f., 391
  - cell wall 28
  - central nervous system (CNS) 402
  - cerebrospinal fluid (CSF) 402
  - chemokines 25, 36, 202, 394
  - cholesterol 96
  - chronic granulomatous disease (CGD) 319
  - chronic infection 319
  - chronic inflammation 29
  - circulating immune complexes (CICs) 238
  - colony-forming units (CFU) 391
  - commensal microbes 23
  - complement 23, 227
  - complement receptor (CR) 92
  - Cornell model 392
  - coronin 1 98
  - costimulation 49ff.
  - C-reactive protein 410
  - C-type lectin receptors (CLRs) 46f.
  - culture filtrate protein (CFP)-10 232
  - cynomolgus macaques 408
  - cytokines 25, 29, 63, 75, 93, 121, 133, 161, 184ff., 327
    - active T cell response 187f.
    - granuloma formation 199
    - in adaptive immunity 92
    - in innate immune response 175ff., 185ff.
    - receptors 327
    - secretion 49ff.
  - cytomegalovirus (CMV) 132
- d**
- database 128
  - delayed-type hypersensitivity (DTH) 191, 354
  - dendritic cell (DC)-specific intercellular adhesion molecule-3-grabbing non integrin (DC-SIGN) 2, 46, 96, 289
  - dendritic cells (DC) 2, 23, 65, 73, 92, 97, 158ff., 185f., 234, 286, 391, 393
    - anti-mycobacterial response 28f.
    - biology 24f.
    - function 24f.
    - inflammatory signature 23ff., 35
    - maturation 24, 28, 35, 48
    - myeloid DCs 24
    - receptors 26
    - response to microbial infections 25
  - determinants 1ff.
  - diagnostics 140
  - dissemination 267
  - draining lymph nodes (DLNs) 45, 47f.
  - drugs 389f., 392
    - development and testing 396
- e**
- early endosome antigen 1 (EEA1) 9, 70, 98
  - early secretory antigen target (ESAT)-6 proteins 124, 135ff., 189, 222ff., 280ff., 341, 365ff., 373, 384
  - endoplasmic reticulum (ER) 103f.
  - endosome 11
  - erythrocyte sedimentation rate (ESR) 410
  - Escherichia coli* 236
  - experimental pulmonary TB
    - dynamics of infection 391, 405
    - pathology 399ff.
  - extensively drug-resistant (XDR) TB 347f.
  - extrapulmonary lesions, pathogenesis 267
- f**
- Fc receptors (FcRs) 3, 95
- g**
- $\gamma^{\delta}$  TCR<sup>+</sup> T cells ( $\gamma^{\delta}$  T cells) 157, 168, 187, 398
    - animal models 171
    - antigens 166
    - development 165
    - function 173
    - general biology 166
    - mycobacterial infection 162
    - phenotype 168
    - receptors 168
    - response to *M. tuberculosis* 168
  - gene expression 36, 395
  - gene hunting 323ff.
  - genetic analysis 306
  - glycolipids 51, 101
  - glycopeptidolipids (GPLs) 4
  - granulocyte-macrophage colony-stimulating factor (GM-CSF) 120
  - granulocytes 262
  - granuloma 229, 234, 236, 246ff., 412
    - architecture 353
    - B cell requirements 252
    - chemokine requirements 256
    - cytokine requirements 252
    - DC requirements 252
    - development 249
    - development in humans 249
    - development in mice 247
    - environment 412
    - formation 201
    - histologic analysis 411
    - macrophage requirements 251

- T cell requirement 251
- types 410
- GTPase 100
- GTP nucleotide exchange factor (GEF) 10
- guinea pig model 397
- advantages 401
- course of disease 397ff.
- immunologic studies 398
- infection 397
- limitations 401
- pathology 399
- strains 397
- vaccine testing 414

**h**

- heat shock proteins (HSP) 125, 169, 376
- hematopoietic stem cells 92
- heparin-binding hemagglutinin (HBHA) 129
- highly active anti-retroviral therapy (HAART) 354
- host adaptation 1ff.
- host cell recognition 6
- host determinants 283ff.
- host immune response 347ff.
- host lipids 11
- host receptors 3
- host recognition 1ff.
- host resistance 370
- host response 394
- human immunodeficiency virus (HIV) 4, 26, 96, 119, 168, 230, 282, 305, 347
- global burden 350
- mononuclear phagocytes 355ff.
- tuberculosis coinfection 347
- human leukocyte antigen (HLA) alleles 128
- human leukocyte antigen (HLA) class II loci 327
- humoral immunity 227f.
- humoral response 227
- Huntington's disease 13
- hypoxia 263

**i**

- immune activation 23
- immunity 279, 285
- immunity-related GTPase (IRG) 100
- immunodominance 135
- immunoglobulin gene rearrangement 227
- immunology 389, 394, 413
- immunopathology 245ff.
- inducible NO synthase (iNOS) 122, 185
- inflammation, regulation 29f.
- innate immunity 73ff.
- innate immunity genes 329ff.

- intercellular adhesion molecule (ICAM) 27, 96
- interferon (IFN)- $\gamma$  185f., 248, 279, 307, 351, 370, 394
- depression of responses 194
- production during active tuberculosis 194
- interferons (IFNs) 23
- interleukin 63
- interleukin (IL)-1 252f.
- interleukin (IL)-10 186ff.
- interleukin (IL)-12 252, 292, 351
- intracellular pathogen resistance (Ipr) gene 107
- invariant natural killer (iNK) T cells 158
- isocitrate lyase (Icl) 102

**k**

- knockout mice 394
- Koch phenomenon 246

**l**

- latency 279ff., 285ff., 370
- definition 279
- evidence 279
- mechanism 283ff.
- protective immunity 283ff.
- latent TB infection (LTBI) 119, 196, 279ff., 355
- lipoarabinomannan (LAM) 27, 67, 90, 104, 230
- lipoglycoconjugates 1
- lipomannan (LM) 2, 67
- lipopolysaccharide (LPS) 25, 163
- liver 391
- lung 3, 28, 45, 48, 120, 248f., 250f., 265, 287, 310, 391, 393, 398, 404, 410ff.
- lung interstitial macrophages 45
- lymph node 28, 257f., 279, 391, 410, 412
- lymphadenopathy 412
- lymphocytes 262, 399
- lymphotoxin (LT)- $\alpha$  201
- lysteriolysin 375

**m**

- macrophage 1ff., 5, 28, 34, 49f., 61ff., 117, 171, 181f., 191, 237ff., 252, 345
- activation 3, 62ff., 103f., 192, 195
- anti-mycobacterial activity 59
- electron micrograph 92
- manipulation by pathogenic mycobacteria 89ff.
- receptor molecules 89f.
- regulation 192
- magnetic resonance imaging 390
- major histocompatibility complex (MHC) 24, 36, 49f., 90, 93, 101ff., 128, 131f., 153, 194, 220, 303, 341

- mammalian cell entry (Mce) proteins 105
  - mannose-capped lipoarabinomannan (ManLAM) 2, 7, 46, 95, 99
  - mannose receptor (MR) 2ff., 7, 46, 93f.
  - Mendelian susceptibility to mycobacterial disease (MSMD) 320f., 313
  - meningitis 393
  - metal ions 316
  - $\beta_2$ -microglobulin ( $\beta_2m$ ) 130
  - mitogen-activated protein kinase (MAPK) 26, 93, 104f., 345
  - modified vaccinia Ankara (MVA) virus 367
  - monkeys 399ff.
  - monocyte chemoattractant protein (MCP) 326
  - monocytes 89, 345
  - mononuclear phagocytes 62, 355ff.
  - multidrug-resistant (MDR) TB 337f.
  - murine model 380ff.
    - course of infection 380ff.
    - drug development and testing 386
    - dynamics of infection and disease 381f.
    - mouse strains 380
    - pathogenesis 385
    - pathology 383
    - route of infection 380f.
    - use of the model 384
    - vaccine development and testing 386
    - variability 381
  - mycobacteria
    - entry into macrophages 46
    - immune responsiveness 333
  - mycobacteria-host interactions 32ff.
  - mycobacterial determinants 1ff.
  - mycobacterial factors 100
    - exported repetitive protein (Erp) 101
    - isocitrate lyase (Icl) 102
    - lipoarabinomannan (LAM) 97
    - mycobacterial glycolipids 101
    - mycobacterial phosphatase SapM 99, 102
    - mycobacterial protein kinase G 102
  - mycobacterial lipid antigens
    - recognition by T cell 159
  - mycobacterial phagosome, modulation 97ff.
  - Mycobacterium avium* 26, 121, 196
  - Mycobacterium bovis* 290, 409
  - Mycobacterium bovis* bacillus Calmette-Guérin (BCG) 4, 26, 46, 190, 196f., 172, 237, 292ff., 308, 316f., 401
    - BCG subunit tandem injection 377
    - boosting with subunit vaccine 379f.
    - cytokine genes 373
    - improved recombinant BCG 373
    - overexpression of antigens 373
  - Mycobacterium leprae* 157
  - Mycobacterium marinum* 416
  - Mycobacterium tuberculosis* 1ff., 10, 28f., 158
    - antigen response 227ff.
    - antigens 125
    - chronic infection 139
    - cytokines 185
    - database 128
    - differential virulence of strains 401
    - exploitation of APC function 52f.
    - $\gamma\delta$  T cells 166
    - gene deletion mutants 372f.
    - gene expression 34, 128
    - genetic analysis of susceptibility 306f.
    - interaction with APC 46
    - interaction with DC and macrophages 45ff.
    - internalization in macrophages 95ff.
    - killing mechanisms of the host 61ff.
    - macrophage receptor 4
    - mouse model of TB infection 307ff.
    - mycobacterial heat shock proteins 125
    - pathogenicity 91
    - route of entry 5ff.
    - secretome 125
    - stage-specific vaccines 141
    - survival 5ff.
    - TLR ligands 51
    - transport to DLNs 47ff.
    - vaccine candidates 372f.
  - mycolic acid 159
- n**
- natural killer (NK) cells 23, 120, 157, 185, 234
  - necrosis 252, 255, 258, 309
  - nitric oxide (NO) 4, 29, 65, 122
  - non-human primate model 408ff.
    - course of infection and disease 409f.
    - drug testing 414
    - immunology 413
    - limitations 415
    - model for AIDS and TB 414
    - mycobacterial species 408
    - non-human primate species 408
    - pathogenesis 413
    - pathology 410
    - uses of the model 413
    - vaccine testing 414
- p**
- paradoxical reactions 358ff.
    - mechanism 359
  - Parkinson's disease 13
  - pathogen-associated molecular patterns (PAMPs) 46
  - pathogenesis 1, 413, 416

- pattern recognition receptors (PRRs) 1, 25, 46, 186  
 peripheral blood mononuclear cells (PBMCs) 194, 290, 354  
 phagocytes 1, 23, 28  
 phagocytic vacuole 315, 316  
 phagocytosis 1ff., 5, 8, 24, 47, 62, 97, 227  
 phagolysosome, biogenesis 9ff., 70  
 phagosome 5, 8, 11, 97, 375  
   – biogenesis 1ff.  
   – maturation 12ff., 70, 71  
   – mycobacterial 97ff.  
 phagosome-lysosome fusion 106  
 phosphatidyl-*myo*-inositolmannosides (PIMs) 2ff., 159  
 phosphoantigens, recognition 168  
 post-translational modification 129  
 primary immunodeficiencies (PID) 306, 319ff.  
 primary lesion complex 258  
   – pathology in BCG vaccinated guinea pigs 268  
   – pathology in drug-treated guinea pigs 269  
 primary lesion necrosis, pathogenesis 262  
 primary lesions  
   – dystrophic calcification 264  
   – hypoxia 263  
   – iron accumulation 263  
 primary lymph node lesions, pathology 264  
 primary pulmonary lesions  
   – acute infection 259  
   – anatomic distribution 258  
   – pathogenesis 259  
   – pathology 258  
 priming 47ff.  
 Pro-Glu (PE) family 128ff., 233, 236  
 Pro-Pro-Glu (PPE) family 128, 233, 236, 375  
 programmed cell death 12  
 proteasome 99, 104, 105, 106  
 protective immunity 279ff.  
 protein kinase G (PknG) 102  
 protein purified derivative 354  
 proteome 228, 230  
 purified protein derivative (PPD) 382, 397
- q**
- quantitative trait loci (QTLs) 311, 313
- r**
- Rab 9  
   – features 10  
   – mechanism of action 10  
   – Rab effectors 10  
   – Rab family 9  
 rabbit model 401  
   – experimental pulmonary TB 405  
   – experimental TB 401  
   – mycobacterial species 401  
   – rabbit species 401  
   – uses of the model 402  
   – vaccine testing 403  
 rapamycin 13, 72  
 reactivation 281ff., 370  
   – epidemiologic risk factors 282f.  
 reactive nitrogen intermediates (RNIs) 66ff., 105, 191  
 reactive oxygen intermediates (ROIs) 4, 66, 105, 185  
 recombinant BCG (r-BCG) constructs 381  
 region of difference (RD) 127, 263  
 reinfection 282  
 resistance loci  
   – BCG locus 315f.  
   – chromosome 1 loci 315  
   – chromosome 7 locus 314f.  
   – chromosome 17 locus 313f.  
   – *lpr1* gene 251f.  
   – *Nramp1* gene 315f.  
   – *sst1* locus 317, 332  
 restriction fragment length polymorphism (RFLP) 281f.  
 resuscitation promoting factor (Rpf)  
   antigens 376  
 rhesus macaques 409f.
- s**
- Salmonella typhimurium* 25ff.  
 scavenger receptors (SRs) 3  
 secondary lesions  
   – associated with airway inflammation 266  
   – pathogenesis 266  
 signal transducer and activator of transcription factor (STAT) 173  
 signal transduction 105  
 simian immunodeficiency virus (SIV) 353f., 408  
 single nucleotide polymorphisms (SNPs) 312  
 spleen 391, 398  
 subunit vaccine 371, 375ff.  
   – BCG subunit tandem injection 377  
   – candidates 375  
   sun exposure 74  
   suppressor of cytokine signaling (SOCS) 31  
 surfactant protein (SP) 3f.  
 surfactants 96  
 susceptibility 305ff.
- t**
- T cell receptor (TCR) 394  
 T cell recognition 140

- T cells 49f., 65f., 74, 105, 119, 157ff., 191, 200, 247ff.
    - activation 30, 47, 49f
    - tuberculosis reactivation 130f.
  - T cell-stimulating antigens 127f.
  - T helper (T<sub>h</sub>) cells 24, 63, 119, 157, 252, 290, 351
    - T<sub>h</sub>1 cells 122
    - T<sub>h</sub>2 cells 123
    - T<sub>h</sub>3 cells 123
  - T suppressor cells 123
    - subdivision 123f.
  - TB/HIV coinfection 349ff., 357
    - CD4 T cells 351ff.
    - HAART 357ff.
  - T<sub>h</sub>1 T cells 122, 191, 195ff.
  - T<sub>h</sub>2 T cells 123, 187, 195
  - T<sub>h</sub>17 (IL-17-producing CD4<sup>+</sup>T) cells 173f., 187
    - relationship with IL-23 and TGF- $\beta$  187
  - Toll-like receptor (TLR) ligands 51, 164, 186
  - Toll-like receptors (TLR) 24ff., 46, 66, 103, 106f., 120, 186, 230, 355f.
    - differential expression 186
    - signaling pathways 329f.
  - transcriptome 35, 236
  - transforming growth factor (TGF)- $\beta$  30, 124, 186
  - transgenic mice 394, 395
  - tryptophan-aspartate-containing coat protein (TACO) 98f.
  - tuberculin skin test (TST) 119, 161, 279ff.
  - tuberculosis (TB) 61, 119, 161, 185, 227, 245, 279, 305, 369, 389f.
    - active disease 232f.
    - aerosol infection 257
    - animal models 389
    - bacterial subpopulations 236
    - CD8<sup>+</sup> T cells 63, 400
    - chronic infection 263ff.
    - course 257
    - disease progressors 250
    - early disease 232
    - genetic control 305ff.
    - genetic spectrum in humans 319f.
    - global burden 350
    - guinea pig model 397ff.
    - history 139
    - HIV coinfection 239ff.
    - host susceptibility 305ff.
    - humoral immunity 227f.
    - identification of susceptibility alleles 321
      - immunopathology 245ff.
      - latent infection 232
      - major susceptibility genes 321, 324
      - mononuclear phagocytes 355ff.
      - MSMD 323
      - murine model 390ff.
      - non-human primate model 408ff.
      - pathogenesis 326
      - pathology 246
      - pathology in guinea pigs compared to humans 257
      - phenotypes 309
      - polygenic susceptibility 322, 326
      - primary TB 305
      - progression 309
      - rabbit model 401
      - reactivation 133
      - recurrent TB 282
      - resistance 165
      - spectrum of disease 237
      - subunit vaccines 375
      - suppressive cytokines 195
      - susceptibility 321
      - treatment 233
      - vaccination strategies 371ff.
      - vaccine 125, 127, 140
  - tuberculous meningitis (TBM) 402
  - tumor necrosis factor (TNF) 49, 63, 105, 119, 161, 185, 250, 284, 354, 393
    - membrane-bound TNF (memTNF) 203
  - tumor necrosis factor receptor (TNFR) 201
- u**
- urease C 375
- v**
- vaccination strategies 369ff., 379
  - vaccination study 290
  - vaccine 125, 138f., 268, 290, 369, 389
    - biomarkers for vaccine trials 383
    - clinical testing 382
    - development and testing 396
    - economic considerations 384
    - hypothetical schemes for novel vaccines 381
    - recombinant vaccines 371
    - subunit vaccines 371f.
  - vaccine candidates 372
  - virulence 267
    - factors 395
  - vitamin D 74, 328
  - vitamin D receptor (VDR) 63, 74, 328